Leuven, Belgium-based Rewind Therapeutics announced on October 6, 2026 that it has secured new financing to advance its lead oral GPR17 antagonist program toward clinical development. The company stated that the capital will support key IND-enabling studies for a therapy designed to promote myelin repair and restore neurological function in people with multiple sclerosis. The announcement follows peer-reviewed preclinical data published in PLOS ONE that demonstrated remyelination and functional recovery in animal models.
Addressing an Unmet Need in Multiple Sclerosis
Multiple sclerosis is a chronic neurological disease characterized by damage to myelin, the protective coating surrounding nerve fibers. While currently available therapies can help control inflammatory disease activity, there are no approved therapies specifically designed to restore lost myelin and repair damaged nerves. Rewind's lead program aims to fill this gap by promoting remyelination and restoring neurological function in affected patients.
Financing to Support Clinical Translation
The financing marks an important milestone for Rewind as it moves its lead program closer to the clinic. The company intends to complete essential IND-enabling studies while expanding preclinical and translational evidence around GPR17 as a target for myelin repair. Rewind described the funding as a step toward its next value-inflection point, though no specific amount was disclosed.
Jim Van heusden, Executive Chair of Rewind Therapeutics, said the additional funding positions the company to advance the GPR17 program toward clinical development. He noted that recent data strengthen confidence in both the biology and the therapeutic potential of GPR17 antagonism. The company is now preparing for the next stage of regulatory and clinical planning.
Preclinical Evidence for Remyelination
In July 2026, Rewind scientists and collaborators at the Netherlands Institute for Neuroscience and Amsterdam UMC published a study titled "Selective GPR17 antagonism enhances structural and functional recovery in animal models of demyelination" in PLOS ONE. The research showed that once-daily oral treatment with a selective Rewind GPR17 antagonist accelerated remyelination of the corpus callosum and optic nerve in acute and chronic cuprizone models. Treatment also produced functional recovery, including normalization of visual evoked potential latency delays and improved spatial memory performance.
Post-mortem analysis of tissue from people with multiple sclerosis showed that GPR17-expressing oligodendrocyte precursor cells accumulate within and around demyelinated lesions, while remyelinated lesions exhibited little or no GPR17. These findings support the role of GPR17 as a key negative regulator of myelin repair. The evidence suggests that blocking GPR17 may allow oligodendrocyte precursor cells to mature and restore damaged myelin.
Scientific Leadership Perspective
Irene Knuesel, PhD, Chief Scientific Officer of Rewind Therapeutics, emphasized that many approaches can demonstrate new myelin formation, but the critical question is whether this translates into functional recovery. She said the company's data show that oral GPR17 antagonism improves both nerve conduction along the visual pathway and cognitive performance. Human MS tissue findings reinforce the underlying biology, according to Knuesel.
Knuesel also noted that emerging preclinical evidence points to a broader role for GPR17 in metabolic regulation, including obesity. This could expand the potential therapeutic relevance of the company's oral GPR17 antagonist beyond multiple sclerosis. The company is advancing the lead program through IND-enabling studies while evaluating additional opportunities linked to GPR17 biology.
Investor Conference Participation
Rewind's management team will be available for meetings at several upcoming industry events, including Optimum Strategic Communications' 18th Annual Healthcare Investor Conference, BIO-Europe 2026, and the Jefferies Global Healthcare Conference. The company plans to discuss its remyelination strategy and recent preclinical findings with investors, analysts, and potential partners. These engagements are expected to support broader awareness of the company's clinical development plans.
Rewind Therapeutics is positioning its oral GPR17 antagonist as a potential first-in-class therapy to address the unmet need for myelin repair in multiple sclerosis. The new financing and published preclinical results support the company's transition toward clinical development. As Rewind advances its lead program through IND-enabling studies, its emerging data may help define a new therapeutic approach for neurological recovery.